Interestingly, different GWAS have reported contrasting findings about the predisposing impact of the ELAC2 A541T variant to prostate cancer (Rebbeck et al, 2000; Suarez et al, 2001; Tavtigian et al, 2001; Vesprini et al, 2001; Wang et al, 2001; Xu et al, 2001), although none of the studies considered the presence of secondary somatic mutations that may be necessary for prostate tumorigenesis (Knudson, 1996). Here, ELAC2 is linked to prostate cancer.